Kay Roscoe collapsed at her Birkenhead home from severe hypoglycaemia after spending two months injecting an unlicensed weight-loss substance purchased online, prompting a stark public warning from medical professionals as private demand for anti-obesity treatments surges.
Unlicensed Weight-Loss Injections Carry Severe Physiological Risks
- Unlicensed black market weight-loss injections carry severe physiological risks, including extreme hypoglycaemia, liver damage, and unverified chemical purity.
- Regulatory bodies lack standard tracking protocols across borders since the Windsor Framework changes, leaving a gap in detecting falsified medicine packs.
The Collapse in Birkenhead
Kay Roscoe, 38, was discovered by a friend on the day they had planned to go out for a roast dinner, unable to speak or stand while frothing at the mouth, BBC News reported. Paramedics rushed her to hospital after her friends explained she had been taking a substance sold as retatrutide, or “reta”, which she had acquired through a friend after scanning a QR code on a pen.
Hospital tests confirmed severe hypoglycaemia, and medical records attributed her emergency admission to an unlicensed weight-loss injection. Doctors warned her she could have died if she had been found just half an hour later.
“I am the luckiest person to be alive. Honestly I can’t say it enough, get off the pens,” Roscoe told BBC News.
Subsequent tests revealed signs of liver damage and high cholesterol, neither of which she had experienced before taking the injections. She said that while she lost a drastic amount of weight during the two-month period, her appetite vanished entirely and she was hardly eating.
“I've never had a problem with anything like this. I just feel run down and drained. My body feels all over the place,” Kay Roscoe said.
Risks of Unlicensed Retatrutide
Retatrutide is an experimental triple-hormone-receptor agonist currently being developed by pharmaceutical company Eli Lilly (NYSE: LLY) as a potential obesity treatment. The drug acts on three receptors, earning it the designation of “triple G,” but it holds no regulatory approval for general use anywhere.
Eli Lilly said that retatrutide cannot legally be sold for human use and that counterfeit and black market alternatives remain unverified and potentially dangerous. The company confirmed it is working alongside the UK’s Medicines and Healthcare products Regulatory Agency (MHRA), police, and social media platforms to remove illegal listings.
Dr Nas Khattak, a research doctor based in Chester who has worked on clinical trials of weight-loss drugs, warned of the hazards associated with unregulated supply chains. “You cannot verify the dose, purity, sterility, or even the contents,” Dr Khattak told BBC News, adding that users often share dosing advice on messaging apps and bodybuilding forums without clinical oversight.
High Costs and Regulatory Gaps Drive Demand for Unverified Injections
High private prescription costs, which can reach up to £2,500 annually, alongside strict NHS eligibility criteria and social media marketing, are driving consumers toward unregulated online vendors, as detailed by Wales Online. Surveys by MedExpress cited in that coverage indicate over 20% of GLP-1 users have purchased unverified injections, with adults aged 25 to 34 showing the highest susceptibility.
Since new arrangements under the Windsor Framework came into force in January 2025, the EU Falsified Medicines Directive—which previously required 2D barcodes and anti-tampering devices checked against a central repository at dispensing—no longer applies in the UK, according to reporting by LabourList.
| Metric / Source | Reported Figure | Context |
|---|---|---|
| Private Purchase Growth | Up 85.7% YoY | Il Sole 24 ORE data on anti-obesity private market surge |
| Social Media Demand | 9% of UK Adults | Ipsos poll finding on acquiring jabs via social media if prescriptions fail |
| User Acquisition Risk | Over 20% | MedExpress survey of GLP-1 users purchasing unverified injections |
Regulatory bodies continue to intercept illicit shipments. The MHRA has previously seized falsified pens at wholesale locations and continues to work alongside international regulators like the European Medicines Agency to restrict unauthorized distribution channels.
Market Outlook and Prevention
As pharmaceutical firms prepare new formulations—such as oral semaglutide, authorized in Europe in July 2026 and expected in pharmacies by 2027, alongside oral orforglipron awaiting final evaluation—market analysts warn that increased product convenience could inadvertently expand opportunities for private secondary-market transfers.
Roscoe, who has received approximately 100 messages from others sharing similar injection experiences since posting her story on Facebook, stated her intention to avoid shortcuts. “Please, everyone, stop taking a needle to be skinny,” she told BBC News.
Disclaimer: The information provided in this article is for educational and informational purposes only and does not constitute financial advice.
